Trials / Unknown
UnknownNCT05016778
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma(POLARIS)
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GPRC5D-CAR-T | After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg. |
Timeline
- Start date
- 2021-06-08
- Primary completion
- 2024-06-30
- Completion
- 2025-06-30
- First posted
- 2021-08-23
- Last updated
- 2022-11-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05016778. Inclusion in this directory is not an endorsement.